Dasom Lee

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

Masooma Rana, Nima Ghalehsari, Alexandria Jensen, Dasom Lee et autres

us (code pays fourni par la source)

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Dasom Lee, Kameron B. Rodrigues, Masooma Rana, Kendall Kozy et autres

us, au (code pays fourni par la source)

From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL

Arash Velayati, Masooma Rana, Alexandria Jensen, Dasom Lee et autres

us (code pays fourni par la source)

POSTER: ABCL-740 Baseline Metabolic Tumor Volume (MTV) as a Prognostic Marker in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Masooma Rana, Nima Ghalehsari, Alexandria Jensen, Dasom Lee et autres

ABCL-740: Baseline Metabolic Tumor Volume (MTV) as a Prognostic Marker in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Masooma Rana, Nima Ghalehsari, Alexandria Jensen, Dasom Lee et autres

Lisocabtagene Maraleucel for Richter's Transformation—A Case Series

Courtney J. Smith, Anmol Goyal, Brian R. Smith, Dasom Lee et autres

us (code pays fourni par la source)

Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and Icans

William Lee Wang, Dasom Lee, Edna Cheung, Alexandria Jensen et autres

us (code pays fourni par la source)

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

Mark Hamilton, Nick A. Phillips, Dasom Lee, Zachary Ehlinger et autres

us (code pays fourni par la source)

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Dasom Lee, Sushma Bharadwaj, Masooma S Rana, Alexandria Jensen et autres

us (code pays fourni par la source)

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

María Silvina Odstrcil Bobillo, Swetha Kambhampati, Dasom Lee, Bradley D. Hunter et autres

us, ch (code pays fourni par la source)

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma

Sushma Bharadwaj, Eric Lau, Mark Hamilton, Anmol Goyal et autres

us (code pays fourni par la source)

Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B‐cell lymphoma in an adolescent patient

Dasom Lee, Anmol Goyal, William Lee Wang, Snegha Ananth et autres

us (code pays fourni par la source)